Imugene (ASX: IMU) has secured full rights to manufacture the cancer immunotherapy Her-Vaxx as part of its acquisition of BioLife Science QLD, which is due to close on December 20th.
The first patent has been assigned to Biolife from Pevion Biotech of Switzerland, protecting Her-Vaxx in major markets until 2030.
Biolife has additionally been granted an exclusive global license from Pevion in the field of oncology covering a patent for the virosome vaccine delivery platform, which is used in the vaccine's manufacture.
Biloife acquired the rights to the novel cancer immunotherapy treatment platform, developed by reseach scientists at the University Medical School in Austria.
The immunotherapy induces an antibody response against breast and gastric cancers.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.